Patents by Inventor Xia Dong

Xia Dong has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NOVEL PHENYLPROPANOID COMPOUND
    Publication number: 20240270779
    Abstract: Provided is a novel active ingredient derived from locust bean and the use thereof. The present invention is a compound represented by the following formula (I) or a salt thereof, or a solvate thereof.
    Type: Application
    Filed: March 14, 2022
    Publication date: August 15, 2024
    Inventors: Karl Wah-Keung TSIM, Takako SAKAI, Tina Ting-Xia DONG, Zhi-Tian PENG, Huai-You WANG, James WEI
  • NOVEL ISOFLAVONE COMPOUND
    Publication number: 20240254156
    Abstract: Provided is a novel active ingredient derived from locust bean and the use thereof. The present invention is a compound represented by the following formula (I) or a salt thereof, or a solvate thereof.
    Type: Application
    Filed: March 14, 2022
    Publication date: August 1, 2024
    Inventors: Karl Wah-Keung TSIM, Takuya YASHIRO, Tina Ting-Xia DONG, Zhi-Tian PENG, Huai-You WANG, Yong LI
  • NOVEL POLYPHENOL COMPOUND
    Publication number: 20240216407
    Abstract: Provided is a novel active ingredient derived from locust bean and the use thereof. The present invention is a compound represented by the following formula (I) or a salt thereof, or a solvate thereof.
    Type: Application
    Filed: March 14, 2022
    Publication date: July 4, 2024
    Inventors: Karl Wah-Keung TSIM, Takuya YASHIRO, Tina Ting-Xia DONG, Zhi-Tian PENG, Huai-You WANG, James WEI
  • Polylactic acid stereocomplex composition, its molded product, a process for its manufacture and its application
    Patent number: 9644095
    Abstract: The instant invention discloses a polylactic acid stereocomplex composition containing pure stereocomplex crystals and a process for its manufacture. The composition according to this invention comprising (a) 30-70 wt % poly (L-lactic acid) (PLLA). (b) 70-30 wt % poly (D-lactic acid) (PDLA) and (c) 0.01-10 wt % nucleating agent, which can be obtained by solution and melt blending. Stereocomplex crystals are preferentially formed according to the invention, and the homocrystals (a crystal form) for the PLLA or PDLA homopolymer can't be observed. The melting temperature of the composition according to the invention is at least 200° C., which is about 30-50° C. higher than the PLLA or PDLA homopolymer.
    Type: Grant
    Filed: March 19, 2014
    Date of Patent: May 9, 2017
    Assignees: Institute of Chemistry, Chinese Academy of Sciences, Purac Biochem B.V.
    Inventors: Xiuqin Zhang, Zujiang Xiong, Guoming Liu, Xia Dong, Tao Wen, Rui Wang, Dujin Wang
  • A POLYLACTIC ACID STEREOCOMPLEX COMPOSITION, ITS MOLDED PRODUCT, A PROCESS FOR ITS MANUFACTURE AND ITS APPLICATION
    Publication number: 20160272811
    Abstract: The instant invention discloses a polylactic acid stereocomplex composition containing pure stereocomplex crystals and a process for its manufacture. The composition according to this invention comprising (a) 30-70 wt % poly (L-lactic acid) (PLLA). (b) 70-30 wt % poly (D-lactic acid) (PDLA) and (c) 0.01-10 wt % nucleating agent, which can be obtained by solution and melt blending. Stereocomplex crystals are preferentially formed according to the invention, and the homocrystals (a crystal form) for the PLLA or PDLA homopolymer can't be observed. The melting temperature of the composition according to the invention is at least 200° C., which is about 30-50° C. higher than the PLLA or PDLA homopolymer.
    Type: Application
    Filed: March 19, 2014
    Publication date: September 22, 2016
    Inventors: Xiuqin Zhang, Zujiang Xiong, Guoming Liu, Xia Dong, Tao Wen, Rui Wang, Dujin Wang
  • Antibodies Directed to Angiopoietin-2 and Uses Thereof
    Publication number: 20080267971
    Abstract: Antibodies directed to the antigen Ang-2 and uses of such antibodies are described. In particular, fully human monoclonal antibodies directed to the antigen Ang-2. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementary determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3. Hybridomas or other cell lines expressing such immunoglobin molecules and monoclonal antibodies.
    Type: Application
    Filed: December 19, 2005
    Publication date: October 30, 2008
    Inventors: Larry L. Green, Qing Zhou, Bruce A. Keyt, Xia-dong Yang, Stephen Charles Emery, David C. Blakey